Low Rates of Transmitted Drug Resistance Among Newly Identified HIV-1 Seroconverters in Rural Rakai, Uganda.
PMID: 27798967
2017
AIDS research and human retroviruses
Abstract: Two individuals had a single non-nucleoside reverse transcriptase inhibitor mutation each, K101E and K103N, and one had a single protease inhibitor mutation, M46I.
Surveillance of Transmitted Drug Resistance in HIV-1-Infected Youths Aged 16 to 25 Years, a Decade After Scale-up of Antiretroviral Therapy in Hebei, China.
PMID: 27750023
2017
AIDS research and human retroviruses
Abstract: All TDR mutations (M46L/I, Y181C, K101E, and G190E) were found only in youths infected with HIV-1 through sexual activity.
Abstract: TDR mutations resided in CRF01_AE (M46I/L and G190E) and subtype B (Y181C and K101E).
Enhanced surveillance of HIV-1 drug resistance in recently infected MSM in the UK.
PMID: 27742812
2017
The Journal of antimicrobial chemotherapy
Abstract: The most common mutations detected at >20% and 2%-20% mutation frequency differed for each drug class, these respectively being: L90M (n = 7) and M46IL (n = 10) for PIs; T215rev (n = 9) and D67GN (n = 4) for NRTIs; and K103N (n = 5) and G190E (n = 2) for NNRTIs.
Comparison of genotypic and virtual phenotypic drug resistance interpretations with laboratory-based phenotypes among CRF01_AE and subtype B HIV-infected individuals.
Result: Protease (PR) RAMs detected from this outlier sample were M46I, I47V and I84V, and reverse transcriptase (RT) RAMs were A62V, D67N, K70R, V75I, F116Y, Q151M and K219Q.
Result: The two most common NNRTI RAMs were V179D (16%) and V106I (15%); the most common NRTI RAMs were D67N (29%) and M184V
Characteristics of Transmitted Drug-Resistant HIV-1 in Recently Infected Treatment-Naive Patients in Japan.
PMID: 26428230
2016
Journal of acquired immune deficiency syndromes (1999)
Abstract: Common mutations in both groups were M46I/L and T215 revertants.
Abstract: The phylogenetic clustering of cases with M46I/L or T215 revertants suggests that HIV with these mutations have become circulating strains.
Unique Flap Conformation in an HIV-1 Protease with High-Level Darunavir Resistance.
Method: M46I, I54V, V82A, M46IN88S, G48VI54V, M46IV82TI84V, and G48VI54VV82A mutations were introduced into the PR coding region, and K103N, Y181C, K103NY181C, K101Q, K101QY181C, K101Q
Table: M46I
Prevalence of Drug Resistance Associated Mutations Among the Anti Retroviral Therapy Exposed HIV-1 Infected Individuals in Manipur, Northeast India.
Abstract: Predominant DRAMs at RT genes were M184V, T215Y, M41L and V108I and H221Y while at PR genes were M46I and I47V.
Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile.
PMID: 27645238
2016
Antimicrobial agents and chemotherapy
Method: The protease inhibitor (PI)-resistant mutant viruses encoding mutations in the HIV-1 protease-coding sequence, L10F/M46I/I50V, I84V/L90M, G48V/I54V/V82S, and G48V/V82A/L90M, were produced in electroporated SupT1 cells via homologous recombination.
From antiretroviral therapy access to provision of third line regimens: evidence of HIV Drug resistance mutations to first and second line regimens among Ugandan adults.
Abstract: Seven of the 36 patients on second line ART had major Protease Inhibitor (PI) associated DRMS including; V82A-7.0%, I54V, M46I and L33I (all 5.0%).
Conclusion: The observed PI resistance mutations (V82A, V82F, V82S, M46I, M46L an
Result: The most common major PI-resistance mutations associated with the highest levels of phenotypic resistance were: V82A:7.0% and I54V, M46I, L33I (all 5.0%).
HIV mutation literature information.
PMID: 
2017
AIDS research and human retroviruses
Browser Board
Co-occurred Entities
Filtrator
ViMRT